Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Study Identifier:
ACH625-003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH-0141625 (Sovaprevir)
  • Drug: Placebo
  • Drug: Pegylated Interferon alpha-2a
  • Drug: Ribavirin
Date
Sep 2010 - Mar 2012
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH-0141625 (Sovaprevir)
  • Drug: Placebo
  • Drug: Pegylated Interferon alpha-2a
  • Drug: Ribavirin
Date
Sep 2010 - Mar 2012
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Los Angeles, California, United States, 90036
Status
N/A
Location
Clinical Trial Site
Los Angeles, California, United States, 90048
Status
N/A
Location
Clinical Trial Site
San Francisco, California, United States, 94115
Status
N/A
Location
Clinical Trial Site
Bradenton, Florida, United States, 34209
Status
N/A
Location
Clinical Trial Site
Orlando, Florida, United States, 32803
Status
N/A
Location
Clinical Trial Site
Chicago, Illinois, United States, 60611
Status
N/A